Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors

Pamela L. Kunz, Diane Reidy‐Lagunes, Lowell Anthony, +14

Pancreas

Tumor BiologyGliomaMedicineNeuroendocrine DisorderPathology +8

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018

Manisha H. Shah, Whitney Goldner, Þorvarður R. Hálfdánarson, +33

Journal of the National Comprehensive Cancer Network

Endocrine OncologySurgical OncologyTumoral PathologyMedicinePrimary Net +11

The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors

James R. Howe, Nipun B. Merchant, Claudius Conrad, +16

Pancreas

Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors

Jennifer A. Chan, Keith Stuart, Craig C. Earle, +9

Journal of Clinical Oncology

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors

Þorvarður R. Hálfdánarson, Jonathan Strosberg, Laura Tang, +16

Pancreas

Neuro-oncologyEndocrine OncologySurgical OncologyPancreatic CancerMedicine +13

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518

James C. Yao, Katherine A. Guthrie, César A. Moran, +11

Journal of Clinical Oncology

ImmunologyPathologyPharmacotherapyIfn ArmEndocrine Oncology +14

Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database

Monica Ter‐Minassian, Jennifer A. Chan, Susanne M. Hooshmand, +9

Endocrine Related Cancer

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study

Alexandria T. Phan, Daniel M. Halperin, Jennifer A. Chan, +7

The Lancet Oncology

MedicinePharmacologyNeuroendocrine DisorderPathologyWell-differentiated Neuroendocrine Tumours +5

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Thomas A. Hope, Lisa Bodei, Jennifer A. Chan, +11

Journal of Nuclear Medicine

EngineeringPatient SelectionPharmacotherapyDifferent Primary OriginRadiation Medicine +17

Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).

Jennifer A. Chan, Jason E. Faris, Janet E. Murphy, +14

Journal of Clinical Oncology

Cancer ManagementPathologyPharmacotherapyEndocrine OncologyPancreatic Cancer +15